Poster presented today in Boston shows direct anti-tumor activity in mesothelioma models, reduced tumor PD-L1 alongside decreased pCREB, and strong TT-4 monotherapy activity with added benefit in anti-PD-1 combinations; TT-4 remains on track for Q1 2026 first-patient dosingDover, DE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is live at th ...